Complaints in Quality Management SystemMayuriMore15
Ìý
Complaints evaluation and handling, Investigation and Determination, CAPA and Return and Recall of products in Quality Management system in pharmaceutical or any industry.
This document discusses complaints and recalls procedures for pharmaceutical products. It outlines the objectives of complaint handling, defines complaint procedures and classifications of defects. Critical defects pose life-threatening risks and require immediate action. Major defects present some risk to patients and require batch recall within days. Other defects have minimal risks. Recall procedures include designating an authorized person to manage the recall according to a standard operating procedure and maintaining distribution records to effectively recall affected products.
Market Complaint Investigation and RecallDhanjay Singh
Ìý
This document discusses market complaints, product recalls, and complaint handling procedures at Simpex Pharma Pvt. Ltd. It defines complaints and explains the need for an effective complaint handling system. Complaints are classified into types A, B, and C based on severity. The complaint handling process involves receiving, investigating, taking corrective actions, and providing feedback to customers. It also defines and classifies product recalls based on health hazard. The duration and types of recalls - voluntary vs forced - are explained. The document states that the Head QA will decide on recalls in consultation with management and key personnel based on defect category.
The document discusses product complaints and recalls in the pharmaceutical industry. It defines a complaint as customer dissatisfaction about a product and outlines four types of complaints. It details the four-step process of handling complaints, which includes receiving, investigating, implementing corrective actions, and reporting. The document also defines a recall as removing a product from distribution due to quality, safety or efficacy issues. It describes the reasons and types of recalls, as well as the classification, levels and timelines involved in an effective recall system.
A Detailed Study on Pharmaceutical Drug RecallTeny Thomas
Ìý
1. A drug recall is a process of removing a pharmaceutical product from distribution due to defects, adverse reactions, or counterfeiting concerns.
2. The objectives of a drug recall are to stop distribution and sale of the affected product, notify relevant parties, efficiently remove the product, and implement corrective actions to prevent future recalls.
3. Recalls are classified by the CDSCO as Class I, II, or III depending on the health risks posed by the defective product. A recall strategy and team must be in place to effectively execute any necessary recalls.
1. The document discusses procedures for handling complaints and product recalls in the pharmaceutical industry. It defines complaints, outlines standard operating procedures for complaint handling, investigation and corrective actions.
2. Recall procedures include classification of recalls based on health hazards, forming a recall team, developing a recall strategy, notifying customers, and terminating a recall once all affected products are removed from the market.
3. Key aspects of complaint handling covered are documentation of complaints, investigating complaints by analyzing customer and retained samples, determining if complaints are confirmed or non-confirmed, and providing feedback to customers.
COMPLAINTS
TOPIC COVERED
1.Definition
2.Principle
3.Need for complaint handling system
4.Objectives
5.Responsibility
6.Type of complaints (CRITICAL,MAJOR ,MINOR)
7.Key for handling complaint
8.Content of product complaint data sheet
9.Steps involved in handling of complaint
10.Recordings of complain
The document discusses complaint handling and product recalls in pharmaceutical companies. It defines a complaint as an expression of customer dissatisfaction and explains the need for an effective complaint handling system to improve quality, maintain regulatory compliance and build customer relationships. It outlines the objectives, responsibilities and types of complaints, as well as the steps to handle complaints which include receiving, investigating, implementing corrective actions, providing feedback and reporting. The document also defines and discusses the objectives, classification, strategy and procedures for conducting an effective product recall.
A COMPLETE STUDY ON COMPLAINTS, DRUG RECALL, RETURNED PRODUCTS, AND WASTE DIS...Teny Thomas
Ìý
a detailed study on complaints, drug recall, returned goods and waste disposal is studied here in the presentation for the students of sixthe semester b.pharm following the PCI syllabus.
The document outlines FDA procedures and responsibilities for product recalls. It discusses how recalls are initiated and classified into three classes based on health hazard. FDA monitors recall effectiveness and will terminate a recall when corrective actions are complete. Recalling firms are responsible for determining the scope and depth of recalls, communicating with FDA and customers, and issuing any necessary press releases. The document provides an overview of drug recalls that occurred in 2013.
This document discusses product complaints and recalls. It defines a complaint as any expression of dissatisfaction with a product. Complaints can come internally from production or quality control or externally from customers. Complaints are classified as critical, major, or minor depending on their severity and health risks. The document outlines guidelines for designating a person to handle complaints, investigating complaints, providing corrective actions and feedback, and analyzing complaint trends. It also defines and discusses the types and procedures for product recalls when serious quality issues are found.
This document discusses market complaints in the pharmaceutical industry. It defines a complaint and outlines different types of customers that complain, including meek, aggressive, high roller, chronic, and rip-off customers. Complaints are classified into A, B, and C types based on their severity, such as adverse drug reactions or major health hazards. The document also covers rules for handling complaints, including thanking customers, training staff, and setting up a logging and analysis process. It emphasizes that complaint handling is important for maintaining customer relationships and identifying manufacturing problems.
Product recalls pose significant financial risks to companies. There are quantitative and qualitative methods to measure recall risk at different stages of the product lifecycle. Firms can take steps to reduce risk through design, quality control processes, and purchasing recall insurance. While voluntary recalls may improve brand perception among consumers, they can negatively impact stock prices in the short term due to investor concerns. It is important for companies to have risk mitigation strategies in place to minimize financial losses from potential recalls.
B PHARAM 6TH SEM
PHARAMACEUTICAL QUALITY ASSURANCE
COMPLAINT
Reasons
Types of Complaint
Steps involved in Handling of complaints
Product Complaint Data Sheet
Complaint Record
Regulatory Guidelines
SOP on Complaint Handling
RECALL
Reasons
Types of Recall
Recall Classification
Levels of Recall
How to Recall the Product?
How To Notify The Consumers?
Regulatory Guidelines
SOP on Product Recall
DRUG RECALL IN 2013 AND 2014
Annual product reviews are conducted annually to assess the quality of drug products and determine if any changes need to be made to product specifications, manufacturing processes, or quality control procedures. The review evaluates analytical data, inspection results, batch failures, complaints, recalls, deviations, stability monitoring results, and corrective actions to verify process consistency and identify quality trends over time. The goal is to continually improve product quality and manufacturing processes.
1) The TGA inspection process for manufacturers faces challenges from high workloads, incomplete sponsor applications, and an increase in identified manufacturing deficiencies requiring follow-up.
2) The TGA and sponsors can both take actions to address these challenges, such as sponsors notifying the TGA early of changes to minimize wasted inspection planning. The TGA is exploring process improvements and incentives to reduce workloads.
3) Common manufacturing deficiencies identified by TGA inspectors include inadequate quality management systems, personnel training, equipment and facility qualification, process validation, and quality control testing. Addressing these deficiencies requires effective manufacturer corrective actions.
The document discusses the selection and certification process for vendors, including defining vendors and the selection process, the purposes of vendor qualification and certification to comply with regulations and for business purposes, and the various types of vendors categorized by the level of testing they perform themselves versus what the manufacturer requires. It also outlines the key factors considered in vendor selection such as reputation, capacity, location, price, and technical evaluation through testing samples.
The document discusses various documentation practices that are important in the pharmaceutical industry. It covers documentation requirements for raw materials, packaging materials, production records, quality control records, and other key areas. Maintaining proper documentation is essential for regulatory compliance, process validation, batch traceability, and ensuring product quality.
This document discusses the importance of certifying vendors that supply raw materials for pharmaceutical manufacturing. Certification helps ensure high quality, safe medicines by preventing issues like contamination, recalls, deaths, and adverse events. It outlines six key steps in the vendor qualification process: 1) supplier selection, 2) due diligence, 3) quality assessment, 4) change control and production assessment, 5) supply chain security, and 6) ongoing monitoring and evaluation. Proper vendor certification and qualification of suppliers is necessary to maintain compliance and minimize risks to patients.
The document discusses quality management systems and the six system inspection model used by the FDA to ensure compliance with cGMP regulations. It describes each of the six systems - quality system, production system, facilities and equipment system, laboratory control system, materials system, and packaging and labeling system. For each system, it provides an overview and lists the relevant cGMP subparts that govern inspections of that system. The goal is to help pharmaceutical manufacturers implement quality systems to meet FDA requirements.
The document discusses key aspects of equipment and raw materials in pharmaceutical quality assurance. It covers topics like equipment selection criteria, purchase specifications, maintenance, calibration, and documentation. For raw materials, it discusses purchase, receiving, sampling, testing, storage and maintenance procedures. Selection of reliable vendors, approved specifications, and ensuring quality of materials is important. Proper identification, storage conditions, and FIFO principle must be followed for raw materials.
Manufacture of Medicinal Products and the Active Pharmaceutical Ingredients (APIs)
used as starting materials in the production of these products is subject to strict good
manufacturing practice regulations that are designed to ensure their quality, safety and
efficacy. This ensures that patients worldwide and at any time can have confidence in the
quality, safety and efficacy of medicines.
The cGMP regulations for final medicinal products are clearly defined in each country
and region. The content of the regulations may vary but the objectives are the same:
- To deliver high quality, safe medicines manufactured and distributed following
controlled procedures to treat diseases and
- To prevent deaths, serious illnesses, adverse events or product recalls resulting from
deficiencies in the manufacturing and distribution processes.
While in the vast majority of cases, the pharmaceutical industry, under the oversight of
the Regulatory Authorities and inspectorates consistently applies appropriate cGMP
practices,
This document provides an overview of quality assurance concepts, including definitions, types of audits, audit reporting, principles of quality audit programs, product audits, and sampling for product audits. It defines quality assurance as the total arrangements to ensure pharmaceutical products are suitable for their intended use. It describes internal, external, and regulatory audits. Audit reports should document findings, recommendations, and corrective actions. Product audits evaluate product quality and compliance to determine fitness for use, while sampling determines sample sizes for auditing mass produced products.
Documentation with respect to release of finished pharmaceutical productMadhuraNewrekar
Ìý
Documentation is a crucial part of the quality assurance system and is needed in every aspect of pharmaceutical manufacturing. Important documentation with respect to final product release in pharmaceutical industry is explained in brief.
This document discusses Good Manufacturing Practices (GMP) for pharmaceutical products as outlined by the World Health Organization (WHO). It provides definitions and explanations of key GMP concepts including quality assurance, quality management, and ensuring consistent production of pharmaceuticals according to appropriate quality standards. It also discusses WHO involvement in establishing GMP guidelines and differences between GMP and current Good Manufacturing Practice (cGMP). The document outlines basic GMP principles for quality management, sanitation, qualification and validation, complaints and recalls, and more. It emphasizes that quality failures can result in regulatory warnings, market withdrawals, supply disruptions, and loss of credibility with patients and regulators.
The webinar discusses current regulatory expectation on how a firm identifies deviations, investigate the cause, recommend corrective, preventive actions.
COMPLAINTS
TOPIC COVERED
1.Definition
2.Principle
3.Need for complaint handling system
4.Objectives
5.Responsibility
6.Type of complaints (CRITICAL,MAJOR ,MINOR)
7.Key for handling complaint
8.Content of product complaint data sheet
9.Steps involved in handling of complaint
10.Recordings of complain
The document discusses complaint handling and product recalls in pharmaceutical companies. It defines a complaint as an expression of customer dissatisfaction and explains the need for an effective complaint handling system to improve quality, maintain regulatory compliance and build customer relationships. It outlines the objectives, responsibilities and types of complaints, as well as the steps to handle complaints which include receiving, investigating, implementing corrective actions, providing feedback and reporting. The document also defines and discusses the objectives, classification, strategy and procedures for conducting an effective product recall.
A COMPLETE STUDY ON COMPLAINTS, DRUG RECALL, RETURNED PRODUCTS, AND WASTE DIS...Teny Thomas
Ìý
a detailed study on complaints, drug recall, returned goods and waste disposal is studied here in the presentation for the students of sixthe semester b.pharm following the PCI syllabus.
The document outlines FDA procedures and responsibilities for product recalls. It discusses how recalls are initiated and classified into three classes based on health hazard. FDA monitors recall effectiveness and will terminate a recall when corrective actions are complete. Recalling firms are responsible for determining the scope and depth of recalls, communicating with FDA and customers, and issuing any necessary press releases. The document provides an overview of drug recalls that occurred in 2013.
This document discusses product complaints and recalls. It defines a complaint as any expression of dissatisfaction with a product. Complaints can come internally from production or quality control or externally from customers. Complaints are classified as critical, major, or minor depending on their severity and health risks. The document outlines guidelines for designating a person to handle complaints, investigating complaints, providing corrective actions and feedback, and analyzing complaint trends. It also defines and discusses the types and procedures for product recalls when serious quality issues are found.
This document discusses market complaints in the pharmaceutical industry. It defines a complaint and outlines different types of customers that complain, including meek, aggressive, high roller, chronic, and rip-off customers. Complaints are classified into A, B, and C types based on their severity, such as adverse drug reactions or major health hazards. The document also covers rules for handling complaints, including thanking customers, training staff, and setting up a logging and analysis process. It emphasizes that complaint handling is important for maintaining customer relationships and identifying manufacturing problems.
Product recalls pose significant financial risks to companies. There are quantitative and qualitative methods to measure recall risk at different stages of the product lifecycle. Firms can take steps to reduce risk through design, quality control processes, and purchasing recall insurance. While voluntary recalls may improve brand perception among consumers, they can negatively impact stock prices in the short term due to investor concerns. It is important for companies to have risk mitigation strategies in place to minimize financial losses from potential recalls.
B PHARAM 6TH SEM
PHARAMACEUTICAL QUALITY ASSURANCE
COMPLAINT
Reasons
Types of Complaint
Steps involved in Handling of complaints
Product Complaint Data Sheet
Complaint Record
Regulatory Guidelines
SOP on Complaint Handling
RECALL
Reasons
Types of Recall
Recall Classification
Levels of Recall
How to Recall the Product?
How To Notify The Consumers?
Regulatory Guidelines
SOP on Product Recall
DRUG RECALL IN 2013 AND 2014
Annual product reviews are conducted annually to assess the quality of drug products and determine if any changes need to be made to product specifications, manufacturing processes, or quality control procedures. The review evaluates analytical data, inspection results, batch failures, complaints, recalls, deviations, stability monitoring results, and corrective actions to verify process consistency and identify quality trends over time. The goal is to continually improve product quality and manufacturing processes.
1) The TGA inspection process for manufacturers faces challenges from high workloads, incomplete sponsor applications, and an increase in identified manufacturing deficiencies requiring follow-up.
2) The TGA and sponsors can both take actions to address these challenges, such as sponsors notifying the TGA early of changes to minimize wasted inspection planning. The TGA is exploring process improvements and incentives to reduce workloads.
3) Common manufacturing deficiencies identified by TGA inspectors include inadequate quality management systems, personnel training, equipment and facility qualification, process validation, and quality control testing. Addressing these deficiencies requires effective manufacturer corrective actions.
The document discusses the selection and certification process for vendors, including defining vendors and the selection process, the purposes of vendor qualification and certification to comply with regulations and for business purposes, and the various types of vendors categorized by the level of testing they perform themselves versus what the manufacturer requires. It also outlines the key factors considered in vendor selection such as reputation, capacity, location, price, and technical evaluation through testing samples.
The document discusses various documentation practices that are important in the pharmaceutical industry. It covers documentation requirements for raw materials, packaging materials, production records, quality control records, and other key areas. Maintaining proper documentation is essential for regulatory compliance, process validation, batch traceability, and ensuring product quality.
This document discusses the importance of certifying vendors that supply raw materials for pharmaceutical manufacturing. Certification helps ensure high quality, safe medicines by preventing issues like contamination, recalls, deaths, and adverse events. It outlines six key steps in the vendor qualification process: 1) supplier selection, 2) due diligence, 3) quality assessment, 4) change control and production assessment, 5) supply chain security, and 6) ongoing monitoring and evaluation. Proper vendor certification and qualification of suppliers is necessary to maintain compliance and minimize risks to patients.
The document discusses quality management systems and the six system inspection model used by the FDA to ensure compliance with cGMP regulations. It describes each of the six systems - quality system, production system, facilities and equipment system, laboratory control system, materials system, and packaging and labeling system. For each system, it provides an overview and lists the relevant cGMP subparts that govern inspections of that system. The goal is to help pharmaceutical manufacturers implement quality systems to meet FDA requirements.
The document discusses key aspects of equipment and raw materials in pharmaceutical quality assurance. It covers topics like equipment selection criteria, purchase specifications, maintenance, calibration, and documentation. For raw materials, it discusses purchase, receiving, sampling, testing, storage and maintenance procedures. Selection of reliable vendors, approved specifications, and ensuring quality of materials is important. Proper identification, storage conditions, and FIFO principle must be followed for raw materials.
Manufacture of Medicinal Products and the Active Pharmaceutical Ingredients (APIs)
used as starting materials in the production of these products is subject to strict good
manufacturing practice regulations that are designed to ensure their quality, safety and
efficacy. This ensures that patients worldwide and at any time can have confidence in the
quality, safety and efficacy of medicines.
The cGMP regulations for final medicinal products are clearly defined in each country
and region. The content of the regulations may vary but the objectives are the same:
- To deliver high quality, safe medicines manufactured and distributed following
controlled procedures to treat diseases and
- To prevent deaths, serious illnesses, adverse events or product recalls resulting from
deficiencies in the manufacturing and distribution processes.
While in the vast majority of cases, the pharmaceutical industry, under the oversight of
the Regulatory Authorities and inspectorates consistently applies appropriate cGMP
practices,
This document provides an overview of quality assurance concepts, including definitions, types of audits, audit reporting, principles of quality audit programs, product audits, and sampling for product audits. It defines quality assurance as the total arrangements to ensure pharmaceutical products are suitable for their intended use. It describes internal, external, and regulatory audits. Audit reports should document findings, recommendations, and corrective actions. Product audits evaluate product quality and compliance to determine fitness for use, while sampling determines sample sizes for auditing mass produced products.
Documentation with respect to release of finished pharmaceutical productMadhuraNewrekar
Ìý
Documentation is a crucial part of the quality assurance system and is needed in every aspect of pharmaceutical manufacturing. Important documentation with respect to final product release in pharmaceutical industry is explained in brief.
This document discusses Good Manufacturing Practices (GMP) for pharmaceutical products as outlined by the World Health Organization (WHO). It provides definitions and explanations of key GMP concepts including quality assurance, quality management, and ensuring consistent production of pharmaceuticals according to appropriate quality standards. It also discusses WHO involvement in establishing GMP guidelines and differences between GMP and current Good Manufacturing Practice (cGMP). The document outlines basic GMP principles for quality management, sanitation, qualification and validation, complaints and recalls, and more. It emphasizes that quality failures can result in regulatory warnings, market withdrawals, supply disruptions, and loss of credibility with patients and regulators.
The webinar discusses current regulatory expectation on how a firm identifies deviations, investigate the cause, recommend corrective, preventive actions.
Corrective actions current expectation of iso 13458 & fda auditorsOnlineCompliance Panel
Ìý
Webinar will provide an understanding of current expectations of ISO 13485 notified body auditors regarding containment or correction of nonconformity.
Webinar on how manufacturers implementing good manufacturing practices managed by quality systems can be in the best compliance with parts 210 and 211.
This document provides information about an online training webinar on effective root cause analysis. The webinar will be led by Betty Lane, an experienced quality assurance consultant. Attendees will learn about root cause analysis techniques and how they can be applied to corrective action systems, process control, and risk management. The webinar objectives are to explain what root cause analysis is, why it is important, and techniques that can be used. Personnel involved in quality management, engineering, auditing and manufacturing would benefit from attending.
The Challenges of an Effective Change Control Program and How to Address OOS ...GlobalCompliancePanel
Ìý
An effective quality system program, along with several regulatory requirements, includes the documentation and evaluation of changes made to validated equipment, utilities, processes and controlled documents.
the challenges of an effective change control program and how to address oos ...GlobalCompliancePanel
Ìý
An effective quality system program, along with several regulatory requirements, includes the documentation and evaluation of changes made to validated equipment, utilities, processes and controlled documents.
Get trained on practical aspects of FDA process validation, equipment qualification, Data analysis, statistical tools for Process Quality Management, more.
Effective remediation of identification problems & errors using rcaOnlineCompliance Panel
Ìý
Root cause analysis is process of conducting analysis to identify physical, human, and contributing factors of an undesirable event. Learn more at this webinar.
This session will discuss all the documents used by FDA to train their inspectors to review your CAPA system, some of which you may not be familiar with.
This document provides an overview of a quality training course, including:
- The importance of participation and confidentiality for all participants.
- The course objectives to introduce quality tools and help organizations develop quality manuals and strategies.
- The syllabus which will cover topics like quality systems, procedures, management aspects, and problem solving techniques.
- Assessment methods including a project, exam, and continuous assessment during the course.
- Recommended reading materials and standards that provide the framework for the course.
This webinar will help you understand whether the acceptance activities are compliant with 21 CFR 820.80 and 820.86, and QSR and Risk Management activities.
This document describes a training package on FDA rules and regulations for medical devices. The package consists of 4 webinar recordings covering topics like device registration and listing, quality management systems, medical device reporting, and implementing unique device identification. The webinars would benefit those working in regulatory affairs, clinical affairs, quality management, and other roles in the medical device industry. The recorded webinars can be accessed via links or CDs and include presentations and reference materials.
Charlie Sodano is an expert in reducing eDiscovery risk for pharmaceutical companies. He has over 20 years of experience managing electronic records at several major pharmaceutical companies. The webinar presentation will provide an effective strategy for pharmaceutical companies to minimize costs associated with litigation and eDiscovery through proper records management practices. It will discuss topics like record policies, litigation holds, and preserving relevant records. The webinar benefits research and development, records management, legal, IT, and validation professionals at pharmaceutical companies.
Why should you attend:
Understand Verification and Validation, differences and how they work together
Develop a "Working Definition" of V&V, Qualification, and related terms
Discuss recent regulatory expectations
Software Verification & Validation requirements of the FDA and ISO.
The latest FDA Software Guidance & Regulations, including Part 11 -impact on V&V strategies
Device and Manufacturing software requirements for V & V
How to determine & demonstrate an appropriate V & V strategy
How to determine & handle software for different Levels of Concern
What V&V is required for 3rd Party software-custom and Off-the-shelf
Impact of FDA, Mobile APPS, Cyber Security, and software standards such as IEC 62304
What to look for during software vendor audits.
V & V documentation and level of detail required for device submissions.
How to document a "risk-based" rationale, and use it in a resource-constrained environment
Determine key "milestones" and "tasks" in a project as well as discussing audience related projects for discussion points
Blind Spots in AI and Formulation Science Knowledge Pyramid (Updated Perspect...Ajaz Hussain
Ìý
This presentation delves into the systemic blind spots within pharmaceutical science and regulatory systems, emphasizing the significance of "inactive ingredients" and their influence on therapeutic equivalence. These blind spots, indicative of normalized systemic failures, go beyond mere chance occurrences and are ingrained deeply enough to compromise decision-making processes and erode trust.
Historical instances like the 1938 FD&C Act and the Generic Drug Scandals underscore how crisis-triggered reforms often fail to address the fundamental issues, perpetuating inefficiencies and hazards.
The narrative advocates a shift from reactive crisis management to proactive, adaptable systems prioritizing continuous enhancement. Key hurdles involve challenging outdated assumptions regarding bioavailability, inadequately funded research ventures, and the impact of vague language in regulatory frameworks.
The rise of large language models (LLMs) presents promising solutions, albeit with accompanying risks necessitating thorough validation and seamless integration.
Tackling these blind spots demands a holistic approach, embracing adaptive learning and a steadfast commitment to self-improvement. By nurturing curiosity, refining regulatory terminology, and judiciously harnessing new technologies, the pharmaceutical sector can progress towards better public health service delivery and ensure the safety, efficacy, and real-world impact of drug products.
How to Configure Restaurants in Odoo 17 Point of SaleCeline George
Ìý
Odoo, a versatile and integrated business management software, excels with its robust Point of Sale (POS) module. This guide delves into the intricacies of configuring restaurants in Odoo 17 POS, unlocking numerous possibilities for streamlined operations and enhanced customer experiences.
How to Manage Putaway Rule in Odoo 17 InventoryCeline George
Ìý
Inventory management is a critical aspect of any business involved in manufacturing or selling products.
Odoo 17 offers a robust inventory management system that can handle complex operations and optimize warehouse efficiency.
Computer Network Unit IV - Lecture Notes - Network LayerMurugan146644
Ìý
Title:
Lecture Notes - Unit IV - The Network Layer
Description:
Welcome to the comprehensive guide on Computer Network concepts, tailored for final year B.Sc. Computer Science students affiliated with Alagappa University. This document covers fundamental principles and advanced topics in Computer Network. PDF content is prepared from the text book Computer Network by Andrew S. Tenanbaum
Key Topics Covered:
Main Topic : The Network Layer
Sub-Topic : Network Layer Design Issues (Store and forward packet switching , service provided to the transport layer, implementation of connection less service, implementation of connection oriented service, Comparision of virtual circuit and datagram subnet), Routing algorithms (Shortest path routing, Flooding , Distance Vector routing algorithm, Link state routing algorithm , hierarchical routing algorithm, broadcast routing, multicast routing algorithm)
Other Link :
1.Introduction to computer network - /slideshow/lecture-notes-introduction-to-computer-network/274183454
2. Physical Layer - /slideshow/lecture-notes-unit-ii-the-physical-layer/274747125
3. Data Link Layer Part 1 : /slideshow/lecture-notes-unit-iii-the-datalink-layer/275288798
Target Audience:
Final year B.Sc. Computer Science students at Alagappa University seeking a solid foundation in Computer Network principles for academic.
About the Author:
Dr. S. Murugan is Associate Professor at Alagappa Government Arts College, Karaikudi. With 23 years of teaching experience in the field of Computer Science, Dr. S. Murugan has a passion for simplifying complex concepts in Computer Network
Disclaimer:
This document is intended for educational purposes only. The content presented here reflects the author’s understanding in the field of Computer Network
Database population in Odoo 18 - Odoo slidesCeline George
Ìý
In this slide, we’ll discuss the database population in Odoo 18. In Odoo, performance analysis of the source code is more important. Database population is one of the methods used to analyze the performance of our code.
QuickBooks Desktop to QuickBooks Online How to Make the MoveTechSoup
Ìý
If you use QuickBooks Desktop and are stressing about moving to QuickBooks Online, in this webinar, get your questions answered and learn tips and tricks to make the process easier for you.
Key Questions:
* When is the best time to make the shift to QuickBooks Online?
* Will my current version of QuickBooks Desktop stop working?
* I have a really old version of QuickBooks. What should I do?
* I run my payroll in QuickBooks Desktop now. How is that affected?
*Does it bring over all my historical data? Are there things that don't come over?
* What are the main differences between QuickBooks Desktop and QuickBooks Online?
* And more
Finals of Rass MELAI : a Music, Entertainment, Literature, Arts and Internet Culture Quiz organized by Conquiztadors, the Quiz society of Sri Venkateswara College under their annual quizzing fest El Dorado 2025.
Mate, a short story by Kate Grenvile.pptxLiny Jenifer
Ìý
A powerpoint presentation on the short story Mate by Kate Greenville. This presentation provides information on Kate Greenville, a character list, plot summary and critical analysis of the short story.
Regulatory requirements (us) for complaint handling in the medical device and pharmaceutical industries
1. Complaint Files, Procedures and
Interrelationship with Complaint Handling,
CAPA, Change Control, Adverse Event
Reporting and Recalls
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com
2. Instructor Profile:
Ms. Vanessa Lopez has held a wide variety of leadership roles in the
Medical Device (Class: I, II, and III), Pharmaceutical (API; Finished Product) and
Environmental regulated industries as well as the Consulting Services industry. She
has worked for Edwards LifeSciences, Roche Diagnostics, Eli Lilly, Pall LifeSciences,
among others. She possesses over 20 years of experience focused on
development, implementation, driving improvements and monitoring of Quality
Assurance, Quality Control, Regulatory Compliance, Regulatory Affairs, Quality
Systems and Supplier Quality activities.
Ms. Lopez has in-depth knowledge, coaches on interpretation and application of
US regulations, EU directives, specific country regulations (Japan, Canada, and
others), national/international standards and guidance documents. She has also
held positions within the CAPA, Material, Safety and Management Review Boards
as well as others.
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com
3. Description:
The course will touch on complaint sources, and details will be furnished
on the interrelationships regarding Complaint Handling/Change Control/Adverse
Event Reporting/and Recalls. The course will also include timeline requirements
associated with adverse event reporting, which reporting formats to use, when to
recall and types of recalls.
In addition, the webinar will incorporate the Complaint Handling Life-Cycle
Process and an example of activities involved in this life cycle. This webinar will
discuss complaint handling implementation challenges, in addition to pitfall
challenges.
At the end of this webinar, there will be a conclusion section, where points to take
into account with the integration of CAPA/Change Control/Adverse Event
Reporting/Recalls/Complaint Files in the Complaint Handling Life-cycle, will be
detailed.
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com
4. Benefite of attending the webinar :
By attending this webinar you will be provided with detailed information
to help you gain a better understanding of the requirements of a complaint
handling system and the interrelationship other regulated activities have with the
referred system. In addition, it will walk you through the complaint handling life-
cycle process by providing you an example of actual activities during this cycle.
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com
5. Objectives of the Presentation:
The following topics will be addressed during this webinar:
 Medical Device and Drug Complaint Handling Requirements (US)
 Complaint Sources
 Interrelationship of Complaint Handling, CAPA, Change Control, Adverse Event
Reporting and Recalls
 Reportable Events, Voluntary and Mandatory Reports, and Reporting timelines
 Complaint Handling Life-Cycle Process (including an example that embraces
activities related to bullet three, above)
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com
6. Who Can Get Benefited:
People who are into Regulatory Compliance Professionals, Quality
Assurance Professionals, Quality Control Professionals, Regulatory Affairs
Professionals, Complaint Handling Professionals, Quality Engineers, Service
Technicians and Engineers, Manufacturing and Design Engineers, Process
Development Personnel, Customer Service Personnel, Sales Representatives will be
more benefited by attending this webinar.
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com
7. How Live Session Works ?
• Username and Password will be sent to you 24 hours prior to the webinar
• Presentation handouts in pdf format will be mailed to you
• Login to the session using the username and password provided to you
• Get answer to your queries through interactive Q&A sessions via chat
• Get certification of attendance.
How Recorded Session Works ?
• A link will be provided to you upon purchase of the recorded session
• Please click on the link to access the session
• Presentation handouts in pdf format will be mailed to you
• Get certification of attendance.
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com
8. Get Connected With Us:
www.onlinecompliancepanel.com
www.onlinecompliancepanel.com | 510-857-5896 | customersupport@onlinecompliancepanel.com